Here at Psychedelic Alpha, we spend a great deal of time writing about the pursuit of regulatory approval for psychedelic medicines, with a key focus on the FDA pipeline, but we also cover other pathways to psychedelic access that don’t hinge on traditional marketing authorisation.While some of those pathways have emerged internationally—such as in Switzerland, Germany, and Australia—certain U.S.
